Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2018 19:31 ET | Source: Mesoblast Limited

Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility

MELBOURNE, Australia and NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it has entered into a US$75 million non-dilutive, four-year...
February 27, 2018 16:47 ET | Source: Mesoblast Limited

Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017

MELBOURNE, Australia and NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with an update on its operational highlights and consolidated...
February 26, 2018 16:00 ET | Source: Mesoblast Limited

2018 First Half Year Financial Results Webcast for Mesoblast

NEW YORK and MELBOURNE, Australia, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first half year ended December...
February 21, 2018 18:00 ET | Source: Mesoblast Limited

Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product...
January 11, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast to Present at 36th Annual J.P. Morgan Healthcare Conference

NEW YORK and MELBOURNE, Australia, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will present a corporate update at the 36th annual J.P. Morgan Healthcare Conference...
December 21, 2017 06:00 ET | Source: Mesoblast Limited

Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices

NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted...
December 20, 2017 06:00 ET | Source: Mesoblast Limited

Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment

NEW YORK and MELBOURNE, Australia, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 3 trial of its proprietary allogeneic mesenchymal stem...
December 14, 2017 19:34 ET | Source: Mesoblast Limited

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

NEW YORK and MELBOURNE, Australia and LEUVEN, Belgium, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) and TiGenix NV (Euronext Brussels:TIG) (Nasdaq:TIG) today announce...
December 07, 2017 17:33 ET | Source: Mesoblast Limited

Mesoblast Named Global Technology Leader in Cell Therapy Industry

NEW YORK and MELBOURNE, Australia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell...
November 16, 2017 06:00 ET | Source: Mesoblast Limited

Chairman’s Address to the Mesoblast 2017 Annual General Meeting

MELBOURNE, Australia and NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Welcome to the Mesoblast 2017 Annual General Meeting. It has been a significant year for Mesoblast. Our proprietary and...